ALISO VIEJO, Calif. and REHOVOT, Israel, Dec. 14 /PRNewswire-FirstCall/ -- Clarient, Inc. (Nasdaq: CLRT), a premier technology and services resource for pathologists, oncologists and the pharmaceutical industry, and BioView Ltd. (TASE: BIOV) today jointly announced that they will collaborate on studies to validate the clinical utility of a non-invasive test for the early detection of non-small cell lung cancer. The test, which uses a patient’s sputum and was originally developed at the University of Texas M.D. Anderson Cancer Center, is expected to be particularly useful to aid in the diagnosis of early stage lung cancer for smokers and other at-risk populations.
